Non-surgical management of knee osteoarthritis: where are we now and where do we need to go?

Frank Buttgereit, Gerd-Rüdiger Burmester, Johannes W J Bijlsma

ABSTRACT

After the successful treatment of inflammatory rheumatic diseases with targeted therapies, the greatest challenge in rheumatic diseases remains the treatment of the most common chronic joint disorder, osteoarthritis (OA). OA is one of the most prevalent chronic diseases worldwide. Globally, hip and knee OA is ranked as the 11th highest contributor to global disability (measured by years lived with disability), and as the 38th highest in terms of overall burden (as measured by disability-adjusted life years) in 2010. With the aging of the population and rising obesity throughout the world, it is anticipated that the burden of OA will increase and become a major problem for health systems globally.

OA commonly affects the knee, with an age-standardised and sex-standardised incidence of 240/100,000 person-years. Over the age of 80 years, more than half of women and one-third of men suffer from radiographical OA of the knee. The global prevalence of radiographically confirmed knee OA (Kellgren-Lawrence grades 2–4) was very recently estimated to be 3.8% (4.8% in females; 2.8% in males) with a peak at around 50 years of age. These data are in agreement with the earlier observation that females are at a higher risk of knee OA than men. A recently published cross-sectional analysis found that women also experience greater knee pain than men, regardless of Kellgren-Lawrence grade. Pain, inflammatory flares, stiffness and loss of movement and function represent major symptoms of OA including knee OA, resulting in a substantial adverse impact on patients’ quality of life and considerable economic burden.

Given this background, proper guidance on the management of OA is needed. This issue has been addressed over recent months in updated guidelines or recommendations detailing three treatment modalities: non-pharmacological, pharmacological and surgical. It should be noted, that OA is not a uniform disease entity. In some patients, progression of the disease seems to be driven by cartilage factors, in others by bone factors or by inflammatory factors. Ongoing research aims to identify potential biomarkers for these different forms of OA. Research is also underway into disease modifying OA drugs (DMOADs) that target different aspects of the disease, treatments for OA pain, and cell-based therapies.

After the successful treatment of inflammatory rheumatic diseases with targeted therapies, the greatest challenge in rheumatic diseases remains the treatment of the most common chronic joint disorder, osteoarthritis (OA). OA is one of the most prevalent chronic diseases worldwide. Globally, hip and knee OA is ranked as the 11th highest contributor to global disability (measured by years lived with disability), and as the 38th highest in terms of overall burden (as measured by disability-adjusted life years) in 2010. With the aging of the population and rising obesity throughout the world, it is anticipated that the burden of OA will increase and become a major problem for health systems globally.
defined OA clinical subphenotypes (knee-only OA with and without comorbidities; multijoint OA with and without comorbidities).

Commonly, we distinguish three treatment modalities: non-pharmacological, pharmacological and surgical. Figure 1 summarises treatments OARSI recommends are ‘Appropriate’ in at least one of the four subphenotypes. 

They suggest not using treatments rated ‘Inappropriate’ (eg, risedronate, electrotherapy), but others are rated ‘Uncertain’ (eg, acupuncture, chondroitin, glucosamine or opioids). For the latter, the authors recommend physician–patient interaction to determine whether this treatment may have merit for an individual patient. Referral for consideration of orthopaedic surgical intervention is indicated after more conservative treatment options have been exhausted. Although both patients and doctors consider postponing surgery a success, for many patients joint replacement is eventually the final treatment option. This implies that, despite the variety of appropriate non-surgical treatment options, there are still considerable limitations in either success rate or tolerability when treating established knee OA.

Excess weight and obesity are well-known risk factors for OA since they increase mechanical stress and induce systemic effects (eg, via adipokines and/or hyperglycaemia) involved in OA pathogenesis. It has recently been confirmed that in knee OA, mechanical stress is the most important underlying mechanism; this in contrast to hand OA, where systemic processes appear to be most important. In line with this are results of a meta-analysis published in July 2014 indicating that knee OA risk increases almost exponentially according to the increase in body mass index (BMI). Furthermore, analysis of data available through the Osteoarthritis Initiative and the CHECK-cohort confirmed that individuals with higher BMI experience greater pain from

**Figure 1** Treatments considered ‘Appropriate’ in at least one of the four subphenotypes of knee osteoarthritis. Quality of evidence is indicated by: bold=good; not bold=fair. NSAIDs, non-steroidal anti-inflammatory drug. * knee braces, knee sleeves, foot orthoses and lateral wedge insoles.

| Treatment option | Studies | Comments |
|------------------|---------|----------|
| DMOADs targeting cartilage | Intra-articular recombinant human fibroblast growth factor 18 (NCT01919164) | Proanabolic growth factor |
| | Intra-articular TPX-100 (NCT1925261) | Chondrogenic peptide |
| DMOADs targeting bone | Oral strontium ranelate | Remodelling of subchondral bone and articular cartilage |
| DMOADs targeting synovitis | Oral hydroxycloroquine and atorvastatin (NCT01645176) | A combination of a DMARD with a statin |
| | Oral methotrexate (NCT01654575) | |
| | Oral SD-6010 (Cindunistat) | |
| | Subcutaneous ABT-981 (NCT01668511) | |
| Treatments targeting pain | Oral Tanezumab (NCT01945346) | Selective inhibitor of inducible nitric oxide synthase |
| | CG100649 (NCT1765296) | Monoclonal antihuman interleukin-1 α/β antibody |
| | AKR 202 (NCT02003118) | Vascular adhesion protein-1 antagonist |
| Cell-based therapies | Allogenic mesenchymal stem cells (NCT01586312, NCT01985563, NCT01459640) | Dual inhibitor of carbonic anhydrase and COX-2 |
| | Mesenchymal trophic factor (NCT02003131) | Small molecule purinergic receptor modulator and enzyme inhibitor |
| | Autologous adipose derived stem cells (NCT01585857) | Induction of interactive biological repair mechanisms involving stem cells |

Table 1 Studies investigating potential new non-surgical treatment options in knee OA (modified and updated from21)

The NCT identification number refers to trials registered in ClinicalTrials.gov (http://clinicaltrials.gov) where more in detail information can be obtained.

DMOAD, disease-modifying antiosteoarthritic drug; DMARD, disease-modifying antirheumatic drug; OA, osteoarthritis.
knee OA than individuals with lower BMI, even when taking into account OA severity. Therefore, successful management of knee OA includes reduction of adverse mechanical factors (ie, weight loss in patients who are overweight or obese). Exercise is also beneficial, as shown in a recently published randomised controlled trial in women with OA of the knee. Progressive resistance exercise reduced pain, improved function, increased strength and showed benefits on some quality of life domains. However, apart from these approaches and education about the disease, there is little to offer patients for prevention or early treatment that is directed at the cause of the disease.

Why have researchers failed so far to develop effective and safe disease modifying OA drugs (DMOADs) for the millions of patients suffering from this serious and disabling disease? One major reason is that pathogenesis of this disease is not fully understood. OA is considered to result from failure of the repair of damaged cartilage. However, recent evidence shows an additional and integrated role of bone and synovial tissue, at least in some patients with OA. Clearly, OA is not a uniform disease entity. In some patients, progression of the disease seems to be driven by cartilage factors, in others by bone factors or by inflammatory factors. Ongoing research aims to identify potential biomarkers for cartilage-driven, bone-driven and synovitis-driven forms of OA. In a very recent intriguing study, Beyer et al identified differentially expressed miRNAs as predictors for severe knee and hip OA. This is an important observation since circulating miRNAs are easily accessible and stable. Only a few biomarkers that reflect bone and cartilage metabolism have shown value in predicting OA, and none has so far entered routine clinical practice. Therefore, specific miRNAs, such as let-7e, may prove useful biomarkers for OA. Research is also underway into DMOADs that target different aspects of the disease, treatments for OA pain and cell-based therapies; table 1 lists studies in these areas that we consider promising. Apart from these novel non-surgical approaches, a new surgical method is also in development–intrinsic cartilage repair by joint distraction.

Despite these widespread and promising current research activities, many questions about OA and its treatment still require answers (box 1). The EU has recognised rheumatic and musculoskeletal diseases as ‘major diseases’, which may trigger research. Priorities in OA research include predictors of progression, understanding mechanisms of pain and tissue communication, developing concepts and interventions for early OA and the need for new treatment strategies. This research agenda represents useful guidance for researchers in the field. We believe that putting as much effort into OA research as was seen in recent years in RA research may yield significant progress in improving quality of life for many patients with OA. Real possibilities are visible on the horizon.

- When does OA start and how can we define this time point?
- Which programmes are most effective to educate patients about the benefits of current preventive measures (such as weight loss and exercise)?
- If a novel DMOAD is discovered how can we select patients who will benefit most (different phenotypes, different points of action)?
- When should surgery be recommended? At an early time point when quality of life is still good or at a later time because of economic restraints and the limited life span of endoprosthesis material?
- Will regenerative medicine (including tissue engineering) result in materials to repair damaged joints that provide an alternative to the metal and ceramics currently used?

### Box 1 Challenges in the treatment of OA

- How do we define the time point when OA begins?
- How can we assess the risk for OA in different populations?
- How can we identify patients who are likely to benefit from different treatments?
- How can we optimize the use of existing treatments?
- How can we develop new treatments for OA?

### Provenance and peer review

Not commissioned; externally peer reviewed.

### Data sharing statement

No additional data are available.

### Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

### REFERENCES

1. Busija L, Bridgett L, Williams SR, et al. Osteoarthritis. Best Pract Res Clin Rheumatol 2010;24:757–68.
2. Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014;73:1323–30.
3. Oliveria SA, Felson DT, Reed JI, et al. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum 1995;38:1134–41.
4. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with reference to clinical practice. Lancet 2011;377:2115–26.
5. Srikanth VK, Fryer JL, Zhai G, et al. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthr Cartilage 2005;13:769–81.
6. Glass N, Segal NA, Sluka KA, et al. Examining sex differences in knee pain: the Multicenter Osteoarthritis Study. Osteoarthr Cartilage 2014;22:1100–5.
7. Rosemann T, Laux G, Szecsenyi J. Osteoarthritis: quality of life, comorbidities, medication and health service utilization assessed in a large sample of primary care patients. J Orthop Surg Res 2007;2:12.
8. Jevsevar DS, Brown GA, Jones DL, et al. The American Academy of Orthopaedic Surgeons evidence-based guideline on: treatment of osteoarthritis of the knee, 2nd edition. J Bone Joint Surg Am 2013;95:1886–96.
9. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64:465–74.
10. Fernandes L, Hagen KB, Bijlsma JW, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis 2013;72:1129–35.
11. Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014;44:253–63.

Buttgereit F, et al. RMD Open 2014;1:e000027. doi:10.1136/rmdopen-2014-000027
12. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage* 2014;22:363–88.

13. Qvist P, Bay-Jensen AC, Christiansen C, et al. The disease modifying osteoarthritis drug (DMOAD): is it in the horizon? *Pharmacol Res* 2008;58:1–7.

14. Visser AW, de Mutsert R, le Cessie S, et al. The relative contribution of mechanical stress and systemic processes in different types of osteoarthritis: the NEO study. *Ann Rheum Dis* 2014; Published Online First: 20 May 2014. doi:10.1136/annrheumdis-2013-205012

15. Zhou ZY, Liu YK, Chen HL, et al. Body mass index and knee osteoarthritis risk: a dose-response meta-analysis. *Obesity* 2014;22:2180–5.

16. Weiss E. Knee osteoarthritis, body mass index and pain: data from the Osteoarthritis Initiative. *Rheumatology* 2014;53:2095–9.

17. Wesseling J, Bierma-Zeinstra SM, Kloppenburg M, et al. Worsening of pain and function over 5 years in individuals with ‘early’ OA is related to structural damage: data from the Osteoarthritis Initiative and CHECK (Cohort Hip & Cohort Knee) study. *Ann Rheum Dis* 2013. Published Online First: 15 Nov 2013. doi:10.1136/annrheumdis-2013-203829

18. Jorge RT, Souza MC, Chiari A, et al. Progressive resistance exercise in women with osteoarthritis of the knee: a randomized controlled trial. *Clin Rehabil* 2014. [Epub ahead of print 3 Jul 2014].

19. Goldring MB, Goldring SR. Osteoarthritis. *J Cell Physiol* 2007;213:626–34.

20. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. *Nat Rev Rheumatol* 2010;6:625–35.

21. Mastbergen SC, Saris DB, Lafeber FP. Functional articular cartilage repair: here, near, or is the best approach not yet clear? *Nat Rev Rheumatol* 2013;9:277–90.

22. Beyer C, Zampetaki A, Lin NY, et al. Signature of circulating microRNAs in osteoarthritis. *Ann Rheum Dis* 2014. Published Online First: 27 Feb 2014. doi:10.1136/annrheumdis-2013-204698

23. Schett G, Kiechl S, Bonora E, et al. Vascular cell adhesion molecule 1 as a predictor of severe osteoarthritis of the hip and knee joints. *Arthritis Rheum* 2009;60:2381–9.

24. Conaghan PG, Kloppenburg M, Schett G, et al. Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee. *Ann Rheum Dis* 2014;73:1442–5.

25. Reginster JY, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. *Ann Rheum Dis* 2013;72:179–86.

26. Pelletier JP, Roubille C, Raynauld JP, et al. Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. *Ann Rheum Dis* 2013. Published Online First 2 Dec 2013. doi:10.1136/annrheumdis-2013-203989

27. Bruyere O, Reginster JY, Bellamy N, et al. Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. *Rheumatology* 2014;53:1457–64.

28. Hellio le Graverand MP, Clemmer RS, Redifer P, et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. *Ann Rheum Dis* 2013;72:187–95.

29. Schnitzer TJ, Ekman EF, Spierings EL, et al. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. *Ann Rheum Dis* 2014. Published Online First: 13 Mar 2014. doi:10.1136/annrheumdis-2013-204905